Levodopa in the treatment of Parkinson's disease

Schapira, A. H. V.; Emre, M.; Jenner, P.; Poewe, W.

doi:10.1111/j.1468-1331.2009.02697.x

Cited by 231Parkinson's Disease Mechanisms and TreatmentsNeurological disorders and treatmentsVoice and Speech Disorders

Levodopa in the treatment of Parkinson's disease

Schapira, A. H. V., Emre, M., Jenner, P., Poewe, W.·2009·European Journal of Neurology

DOI 10.1111/j.1468-1331.2009.02697.x

Open this paper in CoChat — free account

Abstract

The predominant motor features of Parkinson's disease (PD) are caused by degeneration of dopaminergic neurones and can be reversed in part or whole by dopamine replacement or augmentation strategies. Physicians have most experience with the use of levodopa, which remains the most potent oral dopaminergic treatment for PD. There are reservations about the long-term use of levodopa, most particularly in the context of its propensity to induce motor fluctuations and dyskinesias. Strategies exist to delay or diminish these complications, but the physician must lay the basis for these in the selection of drugs for early treatment and the sequence of drugs introduced subsequently. Levodopa efficacy and duration of effect may be enhanced by combination with a catechol-O-methyl transferase inhibitor. Maintaining good motor function and quality of life remain the primary goals of therapy and the principle that treatment must be tailored to the individual patient's needs is paramount.

Integrity signals

Registry

Crossref · 10.1111/j.1468-1331.2009.02697.x

Cites

158 of 158 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Few drugs are currently available to reduce dyskinesias.
“Few drugs are currently available to attenuate dyskinesias (Fahn, 2008;Schapira et al., 2009).”
From Nicotinic receptor-mediated reduction in l-DOPA-induced dyskinesias may occur via desensitization (2010) · cites this paper as Schapira et al., 2009
Dyskinesias occur in most patients after repeated L-DOPA exposure and can be troublesome or disabling.
“These excessive abnormal involuntary movements (AIMs), which occur in the majority of patients with repeated exposure to L-DOPA, can be very troublesome and even disabling (Fahn, 2008;Schapira et al., 2009).”
From Nicotinic receptor-mediated reduction in l-DOPA-induced dyskinesias may occur via desensitization (2010) · cites this paper as Schapira et al., 2009

Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107 · see citing works
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283 · see citing works
Self-citation
Verteilung Von Noradrenalin Und Dopamin (3-Hydroxytyramin) Im Gehirn Des Menschen Und Ihr Verhalten Bei Erkrankungen Des Extrapyramidalen Systems
Ehringer, H., & Hornykiewicz, O. (1960) · Journal of Molecular Medicine · doi:10.1007/bf01485901 · Cited by 1,875 · see citing works
Levodopa and the Progression of Parkinson's Disease
The Parkinson Study Group (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,844 · see citing works
MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE
Schapira, A. H. V., Cooper, J. A. D., Dexter, D. T., Jenner, P. G., Clark, J. B., & MARSDEN, C. D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92366-0 · Cited by 1,757 · see citing works
Self-citation
A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539 · see citing works
Aromatic amino acids and modification of parkinsonism.
Cotzias, G., van Woert, M. H., & Schiffer, L. (1967) · New England Journal of Medicine · doi:10.1056/nejm196702162760703 · Cited by 1,501 · see citing works
Prevalence and Characteristics of Dementia in Parkinson Disease
Aarsland, D., Andersen, K., Larsen, J. O., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,403 · see citing works
Modification of Parkinsonism — Chronic Treatment with L-Dopa
Cotzias, G. C., Papavasiliou, P. S., & Gellene, R. A. (1969) · New England Journal of Medicine · doi:10.1056/nejm196902132800701 · Cited by 1,287 · see citing works
3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists
Carlsson, A., Lindqvist, M., & Magnusson, T. (1957) · Nature · doi:10.1038/1801200a0 · Cited by 1,272 · see citing works
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia
Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy‐Agid, F., Jenner, P., & Marsden, C. D. (1994) · Annals of Neurology · doi:10.1002/ana.410360305 · Cited by 1,161 · see citing works
Self-citation
Oxidative Pathways for Catecholamines in the Genesis of Neuromelanin and Cytotoxic Quinones
GRAHAM, D. G. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13535-9 · Cited by 1,126 · see citing works
Parkinson Disease in Twins
Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R. P., & Langston, J. W. (1999) · JAMA · doi:10.1001/jama.281.4.341 · Cited by 869 · see citing works
Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra
Alam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Marsden, C. D., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031196.x · Cited by 845 · see citing works
Self-citation
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M. R., Reske, S. N., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Rémy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 831 · see citing works
Self-citation
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 800 · see citing works
CENTRAL CERVICAL CORD SYNDROME AFTER HEADING A FOOTBALL
Scoppetta, C., & Vaccario, M. L. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92517-5 · Cited by 755 · see citing works
Parkinson's disease: A disorder due to nigral glutathione deficiency?
Perry, T. L., Godin, D. V., & Hansen, S. (1982) · Neuroscience Letters · doi:10.1016/0304-3940(82)90390-1 · Cited by 753 · see citing works
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
Parkinson Study Group (2002) · JAMA · doi:10.1001/jama.287.13.1653 · Cited by 713 · see citing works
Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease
Schapira, A. H. V., Mann, V. M., Cooper, J. A. D., Dexter, D. T., Daniel, S. E., Jenner, P. G., Clark, J. B., & MARSDEN, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb05809.x · Cited by 673 · see citing works
Self-citation
"ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY
MARSDEN, C. D., & Parkes, J. D. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91416-1 · Cited by 662 · see citing works
Parkinson's Disease Is Associated with Oxidative Damage to Cytoplasmic DNA and RNA in Substantia Nigra Neurons
Zhang, J., Perry, G. L., Smith, M. A., Robertson, D., Olson, S. J., Graham, D. G., & Montine, T. J. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65396-5 · Cited by 636 · see citing works
Treatment of parkinsonism with levodopa.
Yahr, M., Duvoisin, R., Schear, M., Barrett, R. E., & Hoehn, M. M. (1969) · Archives of Neurology · doi:10.1001/archneur.1969.00480160015001 · Cited by 619 · see citing works
Dyskinesias and motor fluctuations in Parkinson's disease
Schrag, A. E., & Quinn, N. P. (2000) · Brain · doi:10.1093/brain/123.11.2297 · Cited by 602 · see citing works
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease
Sofic, E., Lange, K. W., Jellinger, K. A., & Riederer, P. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90355-b · Cited by 591 · see citing works
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-Year Randomized Controlled Trial
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561 · see citing works
Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990
Bower, J. H., Maraganore, D. M., McDonnell, S. K., & Rocca, W. A. (1999) · Neurology · doi:10.1212/wnl.52.6.1214 · Cited by 509 · see citing works
THE BRAIN-STEM LESIONS IN PARKINSONISM
GREENFIELD, J. G., & Bosanquet, F. D. (1953) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.16.4.213 · Cited by 494 · see citing works
Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease
Seibyl, J. P., Marchek, K. L., Quinlan, D. M., Sheff, K., Zoghbi, S. S., Zea‐Ponce, Y., Baldwin, R. M., Fussell, B., Smith, E. O., Charney, D. S., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380407 · Cited by 467 · see citing works
Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Mitchell, I., Clarke, C. E., Boyce, S., Robertson, R. G., Peggs, D., Sambrook, M. A., & Crossman, A. R. (1989) · Neuroscience · doi:10.1016/0306-4522(89)90120-6 · Cited by 461 · see citing works
Risk factors for nursing home placement in advanced Parkinson's disease
Goetz, C. G., & Stebbins, G. T. (1993) · Neurology · doi:10.1212/wnl.43.11.2227 · Cited by 460 · see citing works
Young onset Parkinson's disease
Quinn, N. P., Critchley, P., & MARSDEN, C. D. (1987) · Movement Disorders · doi:10.1002/mds.870020201 · Cited by 450 · see citing works
Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study
Good, P. F., Olanow, C. W., & Perl, D. P. (1992) · Brain Research · doi:10.1016/0006-8993(92)91334-b · Cited by 427 · see citing works
Potential oxidative pathways of brain catecholamines
Tse, D. C. S., McCreery, R. L., & Adams, R. N. (1976) · Journal of Medicinal Chemistry · doi:10.1021/jm00223a008 · Cited by 415 · see citing works
Brain Peroxidase and Catalase in Parkinson Disease
Ambani, L. M., Woert, M. H. V., & Murphy, S. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490440064010 · Cited by 404 · see citing works
The Frequency of Idiopathic Parkinson's Disease by Age, Ethnic Group, and Sex in Northern Manhattan, 1988–1993
Mayeux, R. P., Marder, K. S., COTE, L. J., Denaro, J. E., Hemenegildo, N., Mejia‐Santana, H., Tang, M., Lantigua, R., Wilder, D., Gurland, B. J., et al. (1995) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117721 · Cited by 387 · see citing works
Risk tables for parkinsonism and Parkinson’s disease
Elbaz, A., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., & Rocca, W. A. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00425-5 · Cited by 377 · see citing works
An [18F]dopa–PET and clinical study of the rate of progression in Parkinson’s disease
Morrish, P., Sawle, G. V., & Brooks, D. J. (1996) · Brain · doi:10.1093/brain/119.2.585 · Cited by 366 · see citing works
Complex I Inhibitors Induce Dose‐Dependent Apoptosis in PC12 Cells: Relevance to Parkinson's Disease
Hartley, A., Stone, J. M., Heron, C., Cooper, J. A. D., & Schapira, A. H. V. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63051987.x · Cited by 361 · see citing works
Self-citation
Health related quality of life in Parkinson's disease: a prospective longitudinal study
Karlsen, K. (2000) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.69.5.584 · Cited by 327 · see citing works
Early Treatment of Parkinson??s Disease with Cabergoline Delays the Onset of Motor Complications
Rinne, U. K., Bracco, F., Chouza, C., Dupont, E., Gershanik, O. S., Martí-Massó, J. F., Montastruc, J., & MARSDEN, C. D. (1998) · Drugs · doi:10.2165/00003495-199855001-00004 · Cited by 324 · see citing works
Striatal inhomogeneities and basal ganglia function
Penney, J. B., & Young, A. B. (1986) · Movement Disorders · doi:10.1002/mds.870010102 · Cited by 321 · see citing works
Entacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patients
(1997) · Annals of Neurology · doi:10.1002/ana.410420511 · Cited by 308 · see citing works
Fluctuations of disability in Parkinson's disease – clinical aspects
MARSDEN, C. D., Parkes, J. D., & Quinn, N. P. (1981) · Elsevier eBooks · doi:10.1016/b978-0-407-02295-9.50012-6 · Cited by 306 · see citing works
Glutathione peroxidase activity in Parkinson's disease brain
Kish, S. J., Morito, C. L. H., & Hornykiewicz, O. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90078-3 · Cited by 301 · see citing works
Early development of levodopa‐induced dyskinesias and response fluctuations in young‐onset Parkinson's disease
Kostić, V., Przedborski, S., Flaster, E. R., & Šternić, N. (1991) · Neurology · doi:10.1212/wnl.41.2_part_1.202 · Cited by 298 · see citing works
Neuroprotection in Parkinson Disease
Schapira, A. H. V., & Olanow, C. W. (2004) · JAMA · doi:10.1001/jama.291.3.358 · Cited by 290 · see citing works
Self-citation
Dopamine Neurotoxicity: Inhibition of Mitochondrial Respiration
Ben‐Shachar, D., Zuk, R., & Glinka, Y. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020718.x · Cited by 288 · see citing works
On‐off response
Shoulson, I., Glaubiger, G. A., & Chase, T. N. (1975) · Neurology · doi:10.1212/wnl.25.12.1144 · Cited by 278 · see citing works
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD
Katzenschlager, R., Head, J. A., Schrag, A. E., Ben‐Shlomo, Y., Evans, A. L., & Lees, A. J. (2008) · Neurology · doi:10.1212/01.wnl.0000310812.43352.66 · Cited by 273 · see citing works
Neurodegeneration and neuroprotection in Parkinson disease
Fahn, S., & Sulzer, D. L. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.1.139 · Cited by 266 · see citing works
Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
Hauser, R. A., Rascol, O., Korczyn, A. D., Stoessl, A. J., Watts, R. L., Poewe, W. H., Deyn, P. P. D., & Lang, A. E. (2007) · Movement Disorders · doi:10.1002/mds.21743 · Cited by 252 · see citing works
Self-citation
L-DOPA THERAPY OF PARKINSON’S DISEASE: PLASMA L-DOPA CONCENTRATION, THERAPEUTIC RESPONSE, AND SIDE EFFECTS
Muenter, M. D., & Tyce, G. M. (1971) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(25)07667-0 · Cited by 248 · see citing works
Parkinson Disease, the Effect of Levodopa, and the ELLDOPA Trial
Fahn, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.5.529 · Cited by 246 · see citing works
Toxic and Protective Effects of l ‐DOPA on Mesencephalic Cell Cultures
Mytilineou, C., Han, S., & Cohen, G. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13642.x · Cited by 244 · see citing works
Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.
Walkinshaw, G., & Waters, C. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117946 · Cited by 242 · see citing works
Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease
Mouradian, M. M., Heuser, I. J. E., Baronti, F., & Chase, T. N. (1990) · Annals of Neurology · doi:10.1002/ana.410270105 · Cited by 236 · see citing works
Comparison of Immediate-Release and Controlled Release Carbidopa/Levodopa in Parkinson’s Disease
Block, G. A., Liss, C. L., Reines, S. A., Irr, J. D., & Nibbelink, D. W. (2008) · European Neurology · doi:10.1159/000117399 · Cited by 234 · see citing works
“On‐off” phenomenon with levodopa therapy in parkinsonism
Fahn, S. (1974) · Neurology · doi:10.1212/wnl.24.5.431 · Cited by 230 · see citing works
Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease
Stocchi, F., Vacca, L., Ruggieri, S. A., & Olanow, C. W. (2005) · Archives of Neurology · doi:10.1001/archneur.62.6.905 · Cited by 229 · see citing works
Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons — A possible novel pathogenetic mechanism in Parkinson's disease
Ziv, I., Melamed, E., Nardi, N., et al. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90258-5 · Cited by 222 · see citing works
Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome
Antonini, A., Isaias, I. U., Canesi, M., Zibetti, M., Mancini, F., Manfredi, L., Fante, M. D., Lopiano, L., & Pezzoli, G. (2007) · Movement Disorders · doi:10.1002/mds.21500 · Cited by 218 · see citing works
Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism
Vingerhoets, F. J. G., Snow, B. J., Lee, C. S., Schulzer, M., Mak, E., & Calne, D. B. (1994) · Annals of Neurology · doi:10.1002/ana.410360512 · Cited by 217 · see citing works
Atypical cancer pattern in patients with Parkinson's disease
Olsen, J. H., Friis, S., Frederiksen, K., McLaughlin, J. K., Mellemkjær, L., & Møller, H. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602279 · Cited by 210 · see citing works
Suboptimal medication adherence in Parkinson's disease
Grosset, K. A., Bone, I., & Grosset, D. G. (2005) · Movement Disorders · doi:10.1002/mds.20602 · Cited by 206 · see citing works
A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
Montastruc, J., Rascol, O., Sénard, J., & Rascol, A. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.9.1034 · Cited by 198 · see citing works
Treatment of Parkinson's Syndrome with L Dihydroxyphenylalanine (Levodopa)
MCDOWELL, F. H., LEE, J. E., SWIFT, T., SWEET, R. D., OGSBURY, J. S., & KESSLER, J. T. (1970) · Annals of Internal Medicine · doi:10.7326/0003-4819-72-1-29 · Cited by 183 · see citing works
Timing of treatment initiation in Parkinson's disease: A need for reappraisal?
Schapira, A. H. V., & Obeso, J. A. (2006) · Annals of Neurology · doi:10.1002/ana.20789 · Cited by 177 · see citing works
Self-citation
Parkinsonian Symptomatology An Anatomical and Physiological Analysisaa
MILLER, W. C., & DeLong, M. R. (1988) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1988.tb32998.x · Cited by 170 · see citing works
Tolcapone and fulminant hepatitis
Assal, F., Spahr, L., Hadengue, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(05)61511-5 · Cited by 168 · see citing works
The Significance of Continuous Dopaminergic Stimulation in the Treatment of Parkinson??s Disease
Chase, T. N. (1998) · Drugs · doi:10.2165/00003495-199855001-00001 · Cited by 167 · see citing works
Low‐dose L‐dopa therapy in Parkinson's disease
Poewe, W. H., Lees, A. J., & Stern, G. M. (1986) · Neurology · doi:10.1212/wnl.36.11.1528 · Cited by 163 · see citing works
Self-citation
On‐off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics
Nutt, J. G. (1987) · Annals of Neurology · doi:10.1002/ana.410220415 · Cited by 160 · see citing works
Levodopa
Agid, Y. (1998) · Neurology · doi:10.1212/wnl.50.4.858 · Cited by 157 · see citing works
Treatment Options in the Modern Management of Parkinson Disease
Schapira, A. H. V. (2007) · Archives of Neurology · doi:10.1001/archneur.64.8.1083 · Cited by 154 · see citing works
Self-citation
The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa.
Hely, M. A., Morris, J. G., Reid, W., O'Sullivan, D. J., Williamson, P. M., Rail, D., Broe, G. A., & Margrie, S. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.8.903 · Cited by 154 · see citing works
Oxidative Stress and Parkinson's Diseasea
Owen, A., Schapira, A. H. V., Jenner, P. G., & MARSDEN, C. D. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb39064.x · Cited by 154 · see citing works
Self-citation
Is levodopa toxic?
Fahn, S. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.184s · Cited by 147 · see citing works
Double‐blind, placebo‐controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on‐off' fluctuations
Kurth, M., Tetrud, J. W., Tanner, C. M., et al. (1993) · Neurology · doi:10.1212/wnl.43.9.1698 · Cited by 146 · see citing works
The cytotoxicity of dopamine may be an artefact of cell culture
Clement, M., Long, L. H., Ramalingam, J. K., & Halliwell, B. B. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00802.x · Cited by 140 · see citing works
The evolution and origin of motor complications in Parkinson's disease.
Ja, O., Rodríguez‐Oroz, M., Chaná, P., Lera, G., Rodriguez, M., & Cw, O. (2000) · PubMed · Cited by 140 · see citing works
Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET.
Eidelberg, D., Moeller, J. R., Ishikawa, T., DHAWAN, V. M., Spetsieris, P. G., Chaly, T., Robeson, W., Dahl, J., & Margouleff, D. (1995) · PubMed · Cited by 136 · see citing works
Zur pathologischen Anatomie der Paralysis agitans
Fünfgeld, E. W. (1923) · Zeitschrift für die gesamte Neurologie und Psychiatrie · doi:10.1007/bf02869021 · Cited by 135 · see citing works
Efficacy of unilateral deep brain stimulation of the vim nucleus of the thalamus for essential head tremor
Koller, W. C., Lyons, K. E., Wilkinson, S. B., & Pahwa, R. (1999) · Movement Disorders · doi:10.1002/1531-8257(199909)14:5 · Cited by 132 · see citing works
Nigrostriatal Dopaminergic Neurons Remain Undamaged in Rats Given High Doses of l ‐DOPA and Carbidopa Chronically
Perry, T. L., Yong, V. W., Ito, M., Foulks, J. G., Wall, R. A., Godin, D. V., & Clavier, R. M. (1984) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1984.tb12834.x · Cited by 130 · see citing works
Dopa and dopamine cause cultured neuronal death in the presence of iron
Tanaka, M., Sotomatsu, A., Kanai, H., & Hirai, S. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90046-a · Cited by 127 · see citing works
Long‐term administration of L‐DOPA does not damage dopaminergic neurons in the mouse
Hefti, F. F., Melamed, E., Bhawan, J., & Wurtman, R. J. (1981) · Neurology · doi:10.1212/wnl.31.9.1194 · Cited by 126 · see citing works
Neurotrophic Effects of l ‐DOPA in Postnatal Midbrain Dopamine Neuron/Cortical Astrocyte Cocultures
Mena, M. A., Davila, V., & Sulzer, D. L. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69041398.x · Cited by 125 · see citing works
Double‐blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease
Hauser, R. A., Panisset, M., Abbruzzese, G., et al. (2008) · Movement Disorders · doi:10.1002/mds.22343 · Cited by 121 · see citing works
Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study
Horn, G. V., Schiess, M. C., & Koller, W. C. (2000) · Neurology · doi:10.1212/wnl.55.1.156 · Cited by 119 · see citing works
Mechanisms of Dopamine-Induced Cell Death in Cultured Rat Forebrain Neurons: Interactions with and Differences from Glutamate-Induced Cell Death
Hoyt, K. R., Reynolds, I. J., & Hastings, T. G. (1997) · Experimental Neurology · doi:10.1006/exnr.1996.6374 · Cited by 115 · see citing works
Is levodopa toxic to human substantia nigra?
Rajput, A. H., Fenton, M. E., Birdi, S., et al. (1997) · Movement Disorders · doi:10.1002/mds.870120503 · Cited by 110 · see citing works
Patterns of clinical response and plasma dopa levels in Parkinson's disease
TOLOSA, E. S., Martin, W. E., Cohen, H. P., & JACOBSON, R. L. (1975) · Neurology · doi:10.1212/wnl.25.2.177 · Cited by 110 · see citing works
Long‐term follow‐up of early dopa treatment in Parkinson's disease
Markham, C. H., & Diamond, S. G. (1986) · Annals of Neurology · doi:10.1002/ana.410190410 · Cited by 109 · see citing works
“Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease
Cedarbaum, J. M., Gandy, S., & MCDOWELL, F. H. (1991) · Neurology · doi:10.1212/wnl.41.5.622 · Cited by 108 · see citing works
Factors that influence the occurrence of response variations in Parkinson's disease
de Jong, G. J., Meerwaldt, J. D., & Schmitz, P. I. M. (1987) · Annals of Neurology · doi:10.1002/ana.410220104 · Cited by 107 · see citing works
Pramipexole protects against apoptotic cell death by non‐dopaminergic mechanisms
Gu, M., Irvani, M., Cooper, J. A. D., King, D., Jenner, P. G., & Schapira, A. H. V. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02804.x · Cited by 106 · see citing works
Self-citation
Early-Morning Dystonia
Melamed, E. (1979) · Archives of Neurology · doi:10.1001/archneur.1979.00500410086014 · Cited by 105 · see citing works
Does levodopa aggravate Parkinson's disease?
Blin, J., Bonnet, A.-M., & Agid, Y. (1988) · Neurology · doi:10.1212/wnl.38.9.1410 · Cited by 103 · see citing works
Levodopa-Induced Myoclonus
Klawans, H. L., Goetz, C. G., & Bergen, D. C. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490470075011 · Cited by 102 · see citing works
Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms
Mena, M. A., Casarejos, M. J., Carazo, A., et al. (1997) · Journal of Neural Transmission · doi:10.1007/bf01277654 · Cited by 98 · see citing works
Are Dopamine Receptor Agonists Neuroprotective in Parkinson??s Disease?
Le, W., & Jankovic, J. J. (2001) · Drugs & Aging · doi:10.2165/00002512-200118060-00001 · Cited by 98 · see citing works
Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?
Fiala, K., Whetteckey, J., & Manyam, B. V. (2003) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(03)00040-3 · Cited by 96 · see citing works
Glia conditioned medium protects fetal rat midbrain neurones in culture from L-DOPA toxicity
Mena, M. A., Casarejos, M. J., Carazo, A., et al. (1996) · Neuroreport · doi:10.1097/00001756-199601310-00016 · Cited by 94 · see citing works
Levodopa induces apoptosis in cultured neuronal cells—A possible accelerator of nigrostriatal degeneration in Parkinson's disease?
Ziv, I., Zilkha‐Falb, R., Offen, D., et al. (1997) · Movement Disorders · doi:10.1002/mds.870120105 · Cited by 91 · see citing works
Oxidative stress in Parkinson's disease
Schapira, A. H. V. (1995) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1995.tb01022.x · Cited by 90 · see citing works
Self-citation
Neuroprotection and dopamine agonists
Schapira, A. H. V. (2002) · Neurology · doi:10.1212/wnl.58.suppl_1.s9 · Cited by 86 · see citing works
Self-citation
Pramipexole protects against MPTP toxicity in non‐human primates
Iravani, M., Haddon, C. O., Cooper, J., Jenner, P., & Schapira, A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03625.x · Cited by 85 · see citing works
Self-citation
Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily
Kuoppamäki, M., Korpela, K., Marttila, R. J., et al. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0622-y · Cited by 84 · see citing works
The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa
CARACENI, T., Scigliano, G., & Musicco, M. (1991) · Neurology · doi:10.1212/wnl.41.3.380 · Cited by 83 · see citing works
6-Hydroxydopamine, a new oxidation mechanism
Adams, R. N., Murrill, E. E., McCreery, R. L., et al. (1972) · European Journal of Pharmacology · doi:10.1016/0014-2999(72)90172-0 · Cited by 82 · see citing works
TREATMENT OF PARKINSON'S SYNDROME WITH L-DOPA A DOUBLE BLIND STUDY
Fehling, C. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1966.tb01188.x · Cited by 81 · see citing works
Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson’s disease
Nyholm, D. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.10.1403 · Cited by 81 · see citing works
Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease
Olanow, C. W., Gauger, L. L., & Cedarbaum, J. M. (1991) · Annals of Neurology · doi:10.1002/ana.410290516 · Cited by 79 · see citing works
Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines
Nair, V. D., Olanow, C. W., & Sealfon, S. C. (2003) · Biochemical Journal · doi:10.1042/bj20030017 · Cited by 79 · see citing works
Multiple primary melanoma following administration of levodopa.
Jl, S., Pinckley, J., Gilbert, E. F., et al. (1972) · PubMed · Cited by 78 · see citing works
Levodopa prolongs life expectancy and is non-toxic to substantia nigra
Rajput, A. H. (2001) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(01)00023-2 · Cited by 73 · see citing works
Computational models of the basal ganglia
Gillies, A., & Arbuthnott, G. W. (2000) · Movement Disorders · doi:10.1002/1531-8257(200009)15:5 · Cited by 71 · see citing works
Initial agonist treatment of Parkinson disease
Albin, R. L., & Frey, K. A. (2003) · Neurology · doi:10.1212/01.wnl.0000052681.28286.52 · Cited by 70 · see citing works
Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study
Przuntek, H., Welzel, D., Gerlach, M., et al. (1996) · Journal of Neural Transmission · doi:10.1007/bf01271230 · Cited by 67 · see citing works
Levodopa-Induced Neurotoxicity
Fahn, S. (1997) · CNS Drugs · doi:10.2165/00023210-199708050-00004 · Cited by 66 · see citing works
Mitochondrial respiratory chain function in multiple system atrophy
Gu, M., Gash, M. T., Cooper, J. A. D., Wenning, G. K., Daniel, S. E., Quinn, N. P., MARSDEN, C. D., & Schapira, A. H. V. (1997) · Movement Disorders · doi:10.1002/mds.870120323 · Cited by 66 · see citing works
Self-citation
Dopamine metabolism in Parkinson's disease
Greer, M., & Williams, C. M. (1963) · Neurology · doi:10.1212/wnl.13.1.73 · Cited by 58 · see citing works
The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease
Schapira, A. H. V. (2008) · Movement Disorders · doi:10.1002/mds.22146 · Cited by 56 · see citing works
Self-citation
ADMINISTRATION OF DIHYDROXYPHENYLALANINE TO PARKINSONIAN PATIENTS.
McGeer, P. L., & Zeldowicz, L. R. (1964) · PubMed · Cited by 55 · see citing works
Sur un cas de tremblement parkinsonien hémiplégique symptomatique d'une tumeur du pédoncule cérébral
Blocq, P., & Marinesco, G. (1893) · Medical Entomology and Zoology · Cited by 55 · see citing works
Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells
Korlipara, L. V. P., Cooper, J. M., & Schapira, A. H. V. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.10.015 · Cited by 54 · see citing works
Self-citation
Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects
Russ, H., Müller, T., Woitalla, D., et al. (1999) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s002109900168 · Cited by 54 · see citing works
Dihydroxyphenylalanine in Extrapyramidal Disease
Friedhoff, A. J. (1963) · JAMA · doi:10.1001/jama.1963.73700170010010c · Cited by 50 · see citing works
Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease
Schapira, A. H. V., & Olanow, C. W. (2003) · Annals of Neurology · doi:10.1002/ana.10514 · Cited by 50 · see citing works
Self-citation
Levodopa Therapy and Malignant Melanoma
Sober, A. J. (1978) · JAMA · doi:10.1001/jama.1978.03290060056015 · Cited by 49 · see citing works
Malignant melanoma and levodopa: Is there a relationship? Two new cases and a review of the literature
Pfützner, W., & Przybilla, B. (1997) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(97)80385-4 · Cited by 49 · see citing works
Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys
Lyras, L., Zeng, B. ‐., McKenzie, G. M., Pearce, R. K. B., Halliwell, B. B., & Jenner, P. G. (2002) · Journal of Neural Transmission · doi:10.1007/s702-002-8236-2 · Cited by 48 · see citing works
Self-citation
A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients
Hauser, R. A., Molho, E., Shale, H. M., et al. (1998) · Movement Disorders · doi:10.1002/mds.870130406 · Cited by 47 · see citing works
Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system
Ferrario, J. E., Taravini, I. R. E., Mourlevat, S., Stefano, A. V., Delfino, M. A., Raisman‐Vozari, R., Murer, M. G., Ruberg, M., & Gershanik, O. S. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02595.x · Cited by 46 · see citing works
Levodopa Therapy and the Risk of Malignant Melanoma
Siple, J. F., Schneider, D. C., Wanlass, W., et al. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19150 · Cited by 46 · see citing works
Do dopamine agonists or levodopa modify Parkinson's disease progression?
MAREK, K. L., Jennings, D. L., & Seibyl, J. P. (2002) · European Journal of Neurology · doi:10.1046/j.1468-1331.9.s3.2.x · Cited by 43 · see citing works
Variations in the "on-off" phenomenon.
Duvoisin, R. C. (1974) · PubMed · Cited by 42 · see citing works
The long-duration response to l -dopa in the treatment of early PD
Zappia, M., Oliveri, R. L., Bosco, D., Nicoletti, G., Branca, D., Caracciolo, M., Napoli, I., Gambardella, A., & Quattrone, A. (2000) · Neurology · doi:10.1212/wnl.54.10.1910 · Cited by 41 · see citing works
The "on-off" response to chronic L-DOPA treatment of Parkinsonism.
Rd, S., & MCDOWELL, F. H. (1974) · PubMed · Cited by 38 · see citing works
Response fluctuations in Parkinson's disease
Roos, R. A. C., VREDEVOOGD, C. B., & van der Velde, E. A. (1990) · Neurology · doi:10.1212/wnl.40.9.1344 · Cited by 35 · see citing works
Brain Imaging to Assess the Effects of Dopamine Agonists on Progression of Parkinson Disease
Albin, R. L., Nichols, T. E., & Frey, K. A. (2002) · JAMA · doi:10.1001/jama.288.3.311-a · Cited by 32 · see citing works
Levodopa and melanoma: three cases and review of literature.
Rampen, F. H. J. (1985) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.6.585 · Cited by 31 · see citing works
A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease
Contin, M., Riva, R., Martinelli, P., et al. (1998) · Neurology · doi:10.1212/wnl.51.4.1075 · Cited by 29 · see citing works
A Double Blind Study of l-Dopa Treatment in Parkinson's Disease
Rinne, U. K., & Sonninen, V. H. (2008) · European Neurology · doi:10.1159/000113660 · Cited by 28 · see citing works
Paraneoplastic choreic syndrome during non-Hodgkin's lymphoma
Nuti, A., Ceravolo, R., Salvetti, S., Gambaccini, G., Bonuccelli, U., & Capochiani, E. (2000) · Movement Disorders · doi:10.1002/1531-8257(200003)15:2 · Cited by 27 · see citing works
Newer Medical Treatments in Parkinsonism
SCHWARZ, G. A., & Fahn, S. (1970) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)32643-8 · Cited by 26 · see citing works
Which risk factors predict the levodopa response in fluctuating Parkinson's disease?
Horstink, M. W. I. M., Zijlmans, J. C. M., Pasman, J. W., Berger, H. J. C., Korten, J. J., & Hof, M. A. V. ’. (1990) · Annals of Neurology · doi:10.1002/ana.410270514 · Cited by 25 · see citing works
Problems in Parkinson's disease
MARSDEN, C. D., & Fahn, S. (1981) · Movement Disorders · doi:10.1016/b978-0-407-02295-9.50006-0 · Cited by 24 · see citing works
Variations in the "on-off" effect.
Yahr, M. D. (1974) · PubMed · Cited by 24 · see citing works
Levodopa, melanoma, and Parkinson's disease
Weiner, W. J., Singer, C., Sanchez‐Ramos, J., et al. (1993) · Neurology · doi:10.1212/wnl.43.4.674 · Cited by 23 · see citing works
L ‐dopa does not affect electron transfer chain enzymes and respiration of rat muscle mitochondria
Dagani, F., Ferrari, R., Anderson, J. J., et al. (1991) · Movement Disorders · doi:10.1002/mds.870060408 · Cited by 19 · see citing works
Implications of the 5-year CR FIRST trial
Capildeo, R. (1998) · Neurology · doi:10.1212/wnl.50.6_suppl_6.s15 · Cited by 19 · see citing works
Development of two malignant melanomas during administration of levodopa
Przybilla, B., Schwab, U., Landthaler, M., et al. (1985) · Acta Dermato Venereologica · doi:10.2340/0001555565556557 · Cited by 17 · see citing works
Bimodal administration of entacapone in Parkinson’s disease patients improves motor control
Bet, L., Bareggi, S. R., Pacei, F., et al. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.02043.x · Cited by 16 · see citing works
Quality of life and Parkinson’s disease: The CR FIRST Study
Wasielewski, P. G., & Koller, W. C. (1998) · Journal of Neurology · doi:10.1007/pl00007735 · Cited by 9 · see citing works
Safety of Long-term Levodopa Therapy in Malignant Melanoma
Woofter, M. J. A., & Manyam, B. V. (1994) · Clinical Neuropharmacology · doi:10.1097/00002826-199408000-00002 · Cited by 9 · see citing works
Correlation of Parkinson's disease severity and duration with123I-FP-CIT SPECT striatal uptake
Benamer, H. T. S., Patterson, J., Wyper, D. J., Hadley, D. M., Macphee, G. J. A., & Grosset, D. G. (2000) · Movement Disorders · doi:10.1002/1531-8257(200007)15:4

Flagged first, then by citations

Sorted by citations

Non-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053 · see citing works
Self-citation
Nicotinic receptor-mediated reduction in l-DOPA-induced dyskinesias may occur via desensitization
Bordia, T., Campos, C., McIntosh, J. M., & Quik, M. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162396 · Cited by 82 · see citing works
Perspectives on recent advances in the understanding and treatment of Parkinson's disease
Schapira, A. H., Agid, Y., Barone, P., Jenner, P., Lemke, M. R., Poewe, W., Rascol, O., Reichmann, H., & Tolosa, E. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02793.x · Cited by 69 · see citing works
Self-citation
Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation
Tanaka, M. (2025) · doi:10.20944/preprints202506.2099.v2 · Cited by 57 · see citing works

Levodopa in Parkinson??s Disease
Murer, M. G., Raisman‐Vozari, R., & Gershanik, O. S. (1999) · Drug Safety · doi:10.2165/00002018-199921050-00001 · Cited by 33 · see citing works
Parkinson's disease: medical and surgical treatment
Ahlskog, J. E. (2001) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70036-0 · Cited by 25 · see citing works
Age-Dependent Changes in the Mechanisms Regulating Dopamine Uptake in the Central Nervous System
Missale, C., Govoni, S., Pasinetti, G., et al. (1986) · Journal of Gerontology · doi:10.1093/geronj/41.2.136 · Cited by 19 · see citing works
Effect of ?-phenylethylamine on dopaminergic systems of the rat brain
Zharikov, S. I., Zharikova, A. D., & Budantsev, A. Y. (1980) · Neurophysiology · doi:10.1007/bf01062839
The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease
Schapira, A. H. V. (2008) · Movement Disorders · doi:10.1002/mds.22146 · Cited by 56 · see citing works
Self-citation

Authors: Schapira, A. H. V., Emre, M., Jenner, P., & Poewe, W.
Affiliations: The Royal Free Hospital (GB)
King's College London (GB)
Innsbruck Medical University (AT)
Corresponding author: Schapira, A. H. V.
ORCID: Schapira, A. H. V.
Jenner, P.
Poewe, W.
Venue: European Journal of Neurology
Publisher: Wiley
Published: 2009-08-07
Volume: 16
Issue: 9
Pages: 982-989
ISSN: 1351-5101 (ISSN-L)
1468-1331
DOI: 10.1111/j.1468-1331.2009.02697.x
OpenAlex: W2169510202
Cited by: 231
References: 158
Citations by year: 2026: 7 · 2025: 11 · 2024: 12 · 2023: 11 · 2022: 11 · 2021: 10 · 2020: 11 · 2019: 10 · 2018: 16 · 2017: 9 · 2016: 11 · 2015: 14 · 2014: 20 · 2013: 10 · 2012: 17
FWCI: 2.45
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: European Journal of Neurology (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Topics: Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Neurology › Neurological disorders and treatments
Health Sciences › Medicine › Physiology › Voice and Speech Disorders
Keywords: levodopa, Parkinson's disease, dopaminergic therapy, dopamine replacement therapy, motor fluctuations, dyskinesia, catechol-O-methyltransferase inhibitors, treatment sequencing, quality of life
MeSH terms: Antiparkinson Agents, Dyskinesia, Drug-Induced, Humans, Levodopa, Parkinson Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Levodopa in the treatment of Parkinson's disease

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks